Nanostics in the Media

Press Release: Nanostics Announces New Member of Board of Directors

November 17th, 2022|Article|

Edmonton, Alberta – Nanostics Inc., a precision health diagnostics company, announced today the appointment of Aubrey Rankin to its Board of Directors. Mr. Rankin will join the board of directors at Nanostics replacing Mr. Reg Joseph as one of the independent directors for the company.

“We’re excited to announce Aubrey Rankin’s appointment to Nanostics’ Board of Directors. Aubrey’s vast experience and insights with patient-provider subscription platforms will be invaluable as we launch our lead prostate cancer diagnostic test, ClarityDX Prostate®,” said John Lewis, CEO of Nanostics.

Nanostics sends thanks to outgoing board member Reg Joseph, CEO of Health City, for his service. Reg’s insights into the Healthcare Industry were instrumental in helping Nanostics advance its lead diagnostic product, ClarityDX Prostate® through clinical studies and position it for regulatory approval.

Press Release

News Release: Recognizing 10 years of philanthropic support for prostate cancer research

October 13th, 2022|Article, Press Release|

Two powerhouse researchers in prostate cancer will change the way we treat the disease, thanks to funding from legendary volunteer fundraisers, the Bird Dogs and the Alberta Cancer Foundation.

Working with the Alberta Cancer Foundation and the University of Alberta, the Bird Dogs have enabled a new one-term, five-year chair position to further prostate cancer research — the Bird Dogs Chair in Translational Oncology, a position to be held by researcher Dr. John Lewis. For the last 10 years, Dr. Lewis has held the Frank and Carla Sojonky Chair in Prostate Cancer Research, made possible by a $5 million endowment from the Bird Dogs. Taking over from Dr. Lewis in this position will be surgeon-scientist, Dr. Adam Kinnaird.

News Release

Press Release: Nanostics Receives CE Mark for its ClarityDX Prostate® Test to Detect Clinically Significant Prostate Cancer

August 23rd, 2022|Article|

  • Nanostics’ biomarker and machine learning-powered test, ClarityDX Prostate®, received a CE-IVD Mark.
  • A CE-IVD Mark is required for all in vitro diagnostic (IVD) devices to be placed in the European Economic Area, Iceland, Norway, and Liechtenstein and allows Nanostics to market and sell ClarityDX Prostate® in these countries.
  • The ClarityDX Prostate® test provides patients and physicians with an accurate prediction of clinically significant prostate cancer to support decision-making and improve health outcomes for men suspected of having prostate cancer.
Press Release

Press Release: Nanostics Announces the Launch of its Bladder Cancer Clinical Study Identifying Disease Predictors for Early Detection of Bladder Cancer

July 20th, 2022|Article|

  • Clinical study launched in June 2022 with patient recruitment in Alberta with plans to expand to further sites across North America.
  • The aim of the study is to validate a novel and minimally invasive liquid biopsy test for bladder cancer diagnosis using Nanostics’ ClarityDX® diagnostic platform.
  • The study is supported in part by the Alberta Innovates AICE-Concepts Program with a $600,000 award to Dr. John Lewis, Bird Dogs Chair in Translational Cancer Research at the University of Alberta.
Press Release

Press Release: Nanostics Announces Study Data Supporting ClarityDX Prostate as a Reflex Test to Predict Clinically Significant Prostate Cancer

June 30th, 2022|Article|

Real-world data shows that at a 94% sensitivity level for prostate cancer ClarityDX Prostate® is 147% more specific than the PSA test for predicting clinically significant prostate cancer. Using ClarityDX Prostate® as a reflex test vs. PSA test alone could have resulted in 37% fewer unnecessary biopsies.

Press Release

Nanostics Welcomes New Board Member Mike Schoenberger

October 15th, 2021|Article|

Nanostics is EXCITED to announce Mike Schoenberger as its newest Board Member! We also send a huge THANK YOU to outgoing board member Dale Klein for his dedicated service.

Full Article

Nanostics Re-Opens ClarityDX Prostate Clinical Study with New US Recruitment Site

June 16th, 2020|Article|

PR: Nanostics announced the re-opening of their clinical validation study testing ClarityDX Prostate in a real-world setting. The study is also greatly benefiting from further expansion into the US with the addition of a new patient recruitment site at an award-winning United States clinical research institution. ClarityDX Prostate is a novel liquid biopsy test for the early diagnosis of clinically significant prostate cancer. Nanostics is excited to work with this Partner to reach the recruitment numbers and diversity goals of the clinical study.

Full Article

Nanostics is Developing and Validating a Simple Blood Test to Predict Severity of COVID-19 Disease in SARS-CoV-2 Positive Patients

April 21st, 2020|Article|

PR today: Nanostics to use ClarityDX platform to develop & validate a blood test to predict COVID-19 severity in SARS-CoV-2 patients; with Canadian BioSample Repository in Alberta and Century Clinical Research Institute in Florida.

Full Article

Alberta Impact with Bryce Lambert, Episode 3, ‘Future of Health’ DynaLIFE Accelerator Lab; benefits of this amazing Medical Lab program

January 29th, 2020|Article|

Your technology’s proven in an academic lab⎯now you want it adopted into the healthcare system. The DynaLIFE Accelerator helps startups develop and validate tests in a real-world setting.

Full Article

Validation of ClarityDX Prostate as a Reflex Test to Refine Prediction of Clinically Significant Prostate Cancer: ID: NCT03957252

January 15th, 2020|Article|

Clinical study to validate ClarityDX Prostate as a reflex test to high PSA levels to refine prediction of clinically significant prostate cancer has begun in a prospective cohort of 2800 men.

Full Article

CBC News-Biotech firm recruiting Yukon men for trial, Prostate cancer group says it could save lives

January 12th, 2020|Article|

Alberta-based Nanostics is hoping to recruit 200 Yukoners to the clinical validation study testing ClarityDX Prostate in a real-world setting.

Full Article

CKRW 96.1 FM Radio-Cancer Study Comes to the Yukon

January 9th, 2020|Article|

The Yukon Ride for Dad, which raises money for prostate cancer awareness and research, is making a substantial investment in Nanostic’s research into diagnostic testing for prostate cancer.

Full Article

Movember and Alberta Cancer Foundation campaigns boost prostate cancer screening study

December 3rd, 2019|Article|

News Medical Lifesciences – ClarityDX Prostate cancer diagnostic test validation study gets a boost in recruitment thanks to concurrent fundraising campaigns.

Full Article

ClarityDX Prostate clinical validation study is expanding into the US with Century Clinical Research, Inc.

October 18th, 2019|Article|

The Nanostics & APCaRI co-sponsored ClarityDX Prostate clinical validation study is expanding into the US by opening the Daytona Beach, Florida Century Clinical Research, Inc. recruitment site.

Full Article

Nanostics featured on Alberta Impact Episode 5 with Bryce Lambert

October 3rd, 2019|Article|

1 of 7 Canadian men is diagnosed with prostate cancer each year. We cannot emphasize enough on how important it is to get tested each year. Nanostics has come up with a non-invasive diagnostic test to bring clarity to healthcare decisions. Their core technology is in development to be able to diagnose prostate cancer from a simple blood test.

Full Article

The Cancer Consortium-Nanostics: Advanced Machine Learning to Detect Prostate Cancer

September 27th, 2019|Article|

Nanostics’ core technology, ClarityDX, combines a sensitive extracellular vesicle detection platform with advanced machine learning to diagnose a disease from a simple blood test.

Full Article

Prostate Cancer News Today: Nanostics Launches Pivotal Study to Validate ClarityDX Prostate Diagnostic Test.

June 27th, 2019|Article|

Ana Pena wrote for the Prostate Cancer News Today: The company says the diagnostic tool has the potential to spare many men unnecessary biopsies and treatments.

Full Article

Faculty of Medicine & Dentistry: U of A spin-off company Nanostics launches clinical validation study for ClarityDX Prostate

June 4th, 2019|Article|

NEWS STAFF REPORT: Blood test predicts aggressive prostate cancer with greater accuracy and less patient discomfort.

Full Article

Nanostics and DynaLIFE productive partnership – video interview with Edmonton Journal

May 27th, 2019|Article|

CSO Desmond Pink discusses Nanostics’ productive partnership with DynaLIFE Medical labs’ Translational Research Program- a key relationship to bring ClarityDX to market.

Full Article

Nanostics develops better tests En Route magazine

May 6th, 2019|Article|

Illustration by Martina Paukova

Full Article

Edmonton Journal – New lab brings fledgling health tech companies together in shared space

October 26th, 2018|Article|

A local startup with plans to market a more accurate prostate cancer screening test is one of the first businesses to set up shop in a new downtown shared lab space for health tech companies.

Full Article

A Less Invasive Route to Test For Prostate Cancer

July 26th, 2018|Article|

Alberta scientists, at Nanostics, have created a blood test that could make a significant impact in the way patients are tested and treated for prostate cancer.

Full Article

Funding to develop technology that will detect prostate cancer earlier

May 28th, 2018|Article|

EDMONTON — Alberta Innovates, the Alberta Cancer Foundation and DynaLIFE have joined together to help commercialize Alberta-owned innovations that will detect cancer earlier and improve treatment for Albertans.

Full Article

NVIDIA – How GPU-Powered Cellular Analysis Could Help Avoid Unnecessary Prostate Cancer Biopsies

September 20th, 2017|Article|

1.3M North American men get biopsies each year checking for prostate cancer, many of them unnecessary. UofA researchers want to change that with a new test that relies on GPU computing.

Full Article

Startup Nanostics preparing launch of blood-based biomarker test for prostate cancer

June 26th, 2017|Article|

A new diagnostic will allow men to bypass painful biopsies to test for aggressive prostate cancer.

Full Article

Webinars / Technical Notes

November 3rd, 2022|Event, Webinar|

CanPath Webinar with Dr. John Lewis


Webinar: Predicting diseases through machine learning models

Date: Tuesday, November 22. 2022. New date TBD – please check back for updates.
Venue: Online – for more details and to register go to Event Link
Can Machine Learning models predict disease? Dr. John Lewis,  Bird Dogs Chair in Translational Oncology at the University of Alberta,  and CEO of Nanostics will talk about creating disease prediction models using CanPath questionnaire data, to help us understand the global risk factors of diseases like prostate cancer and how these risk factors differ for different populations.

Liquid biopsy EV analysis with small particle flow cytometry

June 4th, 2022|Event, White Paper|



Small particle flow cytometry using 3 light scatter detectors enhances extracellular vesicle analysis in liquid biopsies, highlighting the potential to segregate EVs by refractive index

Pink, Desmond,  Basu, Arghya, Valencia, Juliana, Pham, Diana, and Lewis, J.D.

Extracellular vesicle analysis using “small particle” flow cytometry would be greatly enhanced if data from materials of different refractive index (RI) could be segregated. Likewise, relative sizing of EVs using small particle flow cytometry is confounded by the influence of RI on light scatter. Beads of different composition and refractive index scatter light differently, so that small beads of high RI and large beads of lower RI can have overlapping signals on a two dimension light scatter plot. As particle size decreases, light scatter intensity profiles eventually merge regardless of refractive index. In this project, we aimed to demonstrate graphically, (1) the enhancement of EV flow analysis when using an additional angle of light scatter collection (medium angle of light scatter, MALS) to identify different sample components (e.g. lipids, protein, extracellular vesicles) and (2) the practical reality of sample component overlap at different particle sizes.

Nanostics CSO Desmond Pink will be presenting this work at CYTO 2022, June 3-7, in Philadelphia, US.
Empowering Scientists. Advancing Cytometry.

Antibody titration for flow cytometric analysis of Extracellular Vesicles: Are cell based protocols up to the task?

October 6th, 2021|Webinar|

Date: 06/10/2021

Time: 10:00 am

Venue: Watch on Demand Now by clicking on the Address Button

Desmond Pink, CSO Nanostics

Why is ANTIBODY TITRATION critical to the success of any flow cytometry experiment?

In this webinar, Desmond Pink will investigate and report on antibody titration considerations for EVs, including sample concentration and processing, conjugate decisions, event triggering, platform differences, data processing and analysis, and real-world examples that highlight when antibody titration is necessary.


White Paper: Performance Qualification for MicroFlow Cytometers: Understanding technical limitations to improve your research

July 6th, 2020|White Paper|

As microflow cytometry matures toward clinical applications for extracellular vesicle (EV) analysis, a concerted effort to improve reproducibility has begun. The new MISEV and MISEV MISEV-Flow guidelines are critical to enabling this reproducibility.


Full Article


ClarityDX Prostate is one of five top picks for mind-blowing technologies and treatments in 2018

January 7th, 2019|Achievement|

Global Edmonton Health reporter Su-Ling Goh highlighted 5 amazing medical technologies and treatments from Edmonton research teams and ClarityDX Prostate was one of them!

Full Article

BioAlberta Recognizes Alberta Innovators and Entrepreneurs at 2018 Awards Gala

September 24th, 2018|Achievement|

CALGARY, Alberta — At its 2018 awards gala, BioAlberta, the province’s life sciences industry association, recognized two leaders for their innovation and achievements. BioAlberta congratulates Circle Cardiovascular Imaging Inc. for winning its Company of the Year award and Dr. John Lewis for winning its Scientific Achievement and Innovation Award.

Full Article


August 29th, 2018|Achievement|

Dr. John Lewis is the winner of the University of Alberta-TEC Edmonton Falling Walls Venture Competition which earned him entrance to the Falling Walls Finale Competition (the International Conference on Future Breakthroughs in Science and Society) which will be held in Berlin this November. Some travel expenses will be paid for.

Full Article
Go to Top